Orchestra BioMed Holdings, Inc. reported $32M of revenue over the trailing twelve months, +986% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $32M (to Q2 2026). Net income: −$59M, trailing twelve months to Q2 2026. Free cash flow: −$59M, trailing twelve months to Q2 2026. Operating margin: −11953%, trailing twelve months to Q2 2026.

OBIOOrchestra BioMed Holdings, Inc.

Healthcare

$5.73+110% 1Y

$5.73

$2.8752 weeks$6.36

OBIO as reported

Orchestra BioMed Holdings, Inc. reported $32M of revenue over the trailing twelve months, +986% on the year before. 10 reported series are charted on this page, each one as filed.

$32M

Revenue, trailing twelve months · to Q2 2026 · +986% against the twelve months before

Net income: −$59M
Net income · −15% year on year · trailing twelve months to Q2 2026
Free cash flow: −$59M
Free cash flow · −1.0% year on year · trailing twelve months to Q2 2026
Operating margin: −11953%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for OBIO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$32M	+986%	Q2 2026
Net income	−$59M	−15%	Q2 2026
EPS	−$0.85	−54%	Q2 2026
Gross margin	84%	n/a	Q2 2026
Operating margin	−11953%	n/a	Q2 2026
Net margin	−12051%	n/a	Q2 2026
ROE	−177%	n/a	Q2 2026
ROA	−56%	n/a	Q2 2026
ROIC	171%	n/a	Q1 2026
Free cash flow	−$59M	−1.0%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.